Verseon (LSE:VERS) Interest Income : £0.33 Mil (TTM As of Jun. 2019)

View and export this data going back to 2015. Start your Free Trial

What is Verseon Interest Income?

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. Verseon's interest income for the six months ended in Jun. 2019 was £0.13 Mil. Its interest income for the trailing twelve months (TTM) ended in Jun. 2019 was £0.33 Mil.

Verseon Interest Income Historical Data

The historical data trend for Verseon's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verseon Interest Income Chart

Verseon Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Interest Income

Get a 7-Day Free Trial

0.25

0.37

0.36

0.33

Verseon Semi-Annual Data
	Dec11	Dec12	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19
Interest Income	Get a 7-Day Free Trial									0.20	0.17	0.12	0.20	0.13

Verseon Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Jun. 2019 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.33 Mil.

Verseon (LSE:VERS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verseon Corp (LSE:VERS) » Definitions » Interest Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

47071 Bayside Parkway, Fremont, CA, USA, 94538

Website

http://www.verseon.com

Verseon Corp is a part of the healthcare sector in the United States. It is a technology-based pharmaceutical company with a computer-driven drug discovery platform. The company designs novel drug candidates that are unlikely to be found using conventional methods. It is also engaged in drug discovery programs such as the diabetic macular edema product candidates, which treat the diseases by controlled disruption of the kallikrein kinin cascade.